Sponsored content provided by Syngenta.
By Eric Tedford, Technical Fungicide Lead at Syngenta
As another season takes off, growers look to you, their retailers, as trusted advisors to help increase the potential of this year’s success. As their partners, they rely on you for agronomic expertise, solutions to their problems, and products that help them get the most out of every acre.Disease and adverse weather impact yield
Many growers have been constantly battling rusts, leaf spots and blights, among other potentially devastating diseases. Growers also consistently combat unpredictable weather, which serves as an added season-long challenge, often hurting the overall strength and health of crops.Latest tool helps growers better fight disease and protect plant health
In 2015, Syngenta received EPA registration for Trivapro® fungicide, an innovative solution to disease control beyond the tools that were available to growers. Containing three different modes of action, Trivapro provides the hardest-working activity on rusts, Northern corn leaf blight, leaf spots, among other troubling diseases. It’s potent SDHI component, Solatenol® works in tandem with azoxystrobin and propiconazole, the strobilurin and triazole modes of action in Trivapro, to deliver an extraordinary level of disease control on row crops in the industry.
Trivapro also offers crop enhancement benefits; it helps slow water loss during dry conditions to improve water use efficiency and reduce crop stress, produces stronger stalks and pods to reduce lodging and increase pod retention, triggers quicker canopy closure to deprive weeds of sunlight, and enables plants to continue photosynthesizing longer to maximize grain fill and yield.Reports from the field
In an effort to win a long-standing battle with stripe rust, Randy James, a wheat grower in Dayton, Washington trialed Trivapro to test its efficacy on wheat. When comparing Trivapro to treatments he typically used, Priaxor® and Propi-Star®, he saw a visually distinctive difference; acres treated with Trivapro fungicide looked exceptionally healthier and had significantly less disease pressure than those treated with the other products, comparing the difference to “night and day.” With Trivapro, James gained a 14 bushel per acre (bu/A) increase in his winter wheat yield over Priaxor and Propi-Star.
Beyond providing long-lasting disease control, growers reaped the crop enhancement benefits Trivapro provided to plants last season. Luke Lauritsen, grower and Golden Harvest® Seed Advisor™ says that Trivapro helped his corn withstand 70 mile-per-hour winds and delivered 45 days of residual disease control. In his Trivapro-treated acres, he saw a 10, 15 and 20 bu/A increase over untreated acres.
Across 48 trials in 2016, the average yield gain for corn growers using Trivapro was 27 bu/A and 92 percent of growers made a profit
. Significant yield bumps were not exclusive to corn trials; versus untreated, Trivapro plots showed average yield increases of 8 bu/A in soybeans
and 13 bu/A in wheat
As an organization, we are constantly working toward developments to assist growers in tackling yield threats and maximizing their return on investment. Our experts are consistently pushing to be on the forefront of innovation and technology, and as a company, we’re continuing to create new tools before issues erupt.
To learn more about Trivapro fungicide, visit www.NotAfraidToWork.com
Product performance assumes disease presence.
©2017 Syngenta. Important: Always read and follow label instructions. Some products may not be registered for sale or use in all states or counties. Please check with your local extension service to ensure registration status.
Trivapro®, Solatenol®, the Alliance Frame, Purpose Icon and the Syngenta logo are registered trademarks of a Syngenta Group Company. All other trademarks are the property of their respective owners.
Data from 48 non-replicated hybrid/locations. ROI calculation based on commodity price of $3.50/bu corn, Trivapro cost of $17/acre and $10 R1 application cost.
Based on 9 large plot trials in the U.S. in 2016.
Based on 21 replicated trials in the U.S. in 2016.